Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression

Anti-Cancer Drugs

Volumn 19, Issue 3, 2008, Pages 247-255

  Zhou, Hui Jun ^a,b   Wang, Zeng ^a   Li, Ao ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2 and Bax; Caspase 3; Dihydroartemisinin; Leukemia; Transferrin receptor

Indexed keywords

CASPASE 3; DIHYDROARTEMISININ; DNA FRAGMENT; PROTEIN BAX; PROTEIN BCL 2; TRANSFERRIN RECEPTOR; TRYPAN BLUE; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; DIHYDROQUINGHAOSU; SESQUITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL STRAIN HL 60; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INDUCTION; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING; DNA FRAGMENTATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; STAINING; TIME;

ANTIMALARIALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TRANSFERRIN; SESQUITERPENES; STAINING AND LABELING; TIME FACTORS; TRYPAN BLUE;

EID: 45549109486     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f3f152     Document Type: Article

References (34)

1. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32:1655-1660.
2. O'Neill PM, Posner GH. A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 2004; 47:2945-2964.
3. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341:603-608.
4. Posner GH, O'Neill PM. Knowledge of the proposed chemical mechanism of action and cytochrome P450 metabolism of antimalarial trioxanes like artemisinin allows rational design of new antimalarial peroxides. Acc Chem Res 2004; 37:397-404.
5. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18: 767-773.
6. Lai H, Singh NP. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 2001; 70:49-56.
7. Gary LD, Astrid CB, Katie AK, Hang Y, Jose AC, Clare AT, et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 2005; 5:10854-10861.
8. Disbrow GL, Baege AC, Kierpiec KA, Yuan H, Centeno JA, Thibodeaux CA, et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 2005; 65:10854-10861.
9. Kwok JC, Richardson DR. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 2002; 42:65-78.
10. May WS, Cuatrecasas P. Transferrin receptor: its biological significance. J Membrane Biol 1985; 88:205-215.
11. O'Donnell K, Yu D, Zeller KI, Kim J, Racke F, Thomas-Tikhonenko A, Dang CV. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol 2006; 26:2373-2386.
12. Fukuchi K, Tomoyasu S, Tsuruoka N, Gomi K. Iron deprivation induced apoptosis in HL-60 cell. FEBS Lett 1994; 350:139-142.
13. Truksa J, Kovár J, Valenta T, Ehrlichova M, Polák J, Naumann PW. Iron deprivation induces apoptosis independently of p53 in human and murine tumour cells. Cell Prolif 2003; 36;:199-213.
14. Jeffrey SA. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006; 147:239-248.
15. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281:1312-1316.
16. Subhashini J, Mahipal SVK, Reddanna P. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 2005; 224:31-43.
17. Reddy CM, Bhat VB, Kiranmai G, Reddy MN, Reddanna P, Madyastha KM. Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis. Biochem Biophys Res Commun 2000; 277:599-603.
18. Martin B, Regina T, Nihay L, Rachel E, Patrice D, Francois A. Lemonnier and Steve Pascolo. Expression of iron transport proteins divalent metal transporter-1, Ferroportin-1, HFE and transferrin receptor-1 in human monocyte-derived dendritic cells. Cell Biochem Funct 2007; 25:287-296.
19. Holmes DI, Zachary I. Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors. FEBS Lett 2004; 557:93-98.
20. Lee J, Zhou HJ, Wu XH. Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. Cancer Chemother Pharmacol 2006; 57:213-220.
21. Wu XH, Zhou HJ, Lee J. Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. Anticancer Drugs 2006; 17:839-848.
22. Szotowski B, Antoniak S, Goldin-Lang Pa, Quoc-Viet T, Klaus P, Rosenthal P, et al. Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. Cardiovasc Res 2007; 73:806-812.
23. Kim SJ, Kim MS, Lee JW, Lee CH, Yoo H, Shin SH, et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol 2006; 132:129-135.
24. Gupta AD, Shah VI. Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Hematol Pathol 1990; 4:37-41.
25. Tracy RD, Tracie D, Jose AR, Gustavo H, Manuel LP. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006; 121:144-158.
26. Calzolari A, Oliviero I, Deaglio S, Mariani G, Biffoni M, Sposi NM, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells, Mol Dis 2007; 39:82-91.
27. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-257.
28. Rello S, Stockert JC, Moreno V, Gamez A, Pacheco M, Juarranz A, et al. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis 2005; 10:201-208.
29. Konstantinidou AE, Korkolopoulou P, Patsouris E. Apoptotic markers for tumor recurrence: a mini review. Apoptosis 2002; 7:461-470.
30. Karen MH, John JT. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999; 59:3077-3083.
31. Woong N, Jungae T, Ju-Kyoung R, Mankil J, Jong-In Y, Hyung-Jun K, In-Ho C. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck 2007; 10:335-340.
32. Belinda CB, Sharad K. Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 2002; 20:63-74.
33. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-619.
34. l. J Biol Chem 1999; 274:2225-2233.